<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04506151</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0374</org_study_id>
    <secondary_id>1R01DK121726</secondary_id>
    <nct_id>NCT04506151</nct_id>
  </id_info>
  <brief_title>Sleep Optimization to Improve Glycemic Control in Adults With Type 1 Diabetes</brief_title>
  <official_title>Sleep Optimization to Improve Glycemic Control in Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 40% of adults with type 1 diabetes have insufficient sleep which is associated with&#xD;
      negative health consequences including poor blood glucose control and greater diabetes&#xD;
      complications. In this study, a sleep intervention (Sleep-Opt) that uses wearable sleep&#xD;
      tracking technology, telephone coaching and informational content designed to improve sleep&#xD;
      and glycemic control in working-age adults with type 1 diabetes. Sleep-Opt could lead to&#xD;
      reduced development of diabetes complications and improve quality of life for adults with&#xD;
      type 1 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite improvements in treatment regimens and technology, less than 20% of adults with type&#xD;
      1 diabetes (T1D) achieve glycemic targets. Sleep is increasingly recognized as a potentially&#xD;
      modifiable target for improving glycemic control. Diabetes distress, poor self-management&#xD;
      behaviors, and reduced quality of life (QoL) have also been linked to sleep variability and&#xD;
      insufficient sleep duration. The American Diabetes Association Standards of Medical Care in&#xD;
      Diabetes incorporated sleep as an important component of the medical evaluation in persons&#xD;
      with diabetes. However, no specific recommendation was given as to how to improve sleep. A&#xD;
      significant gap of knowledge exists regarding the effects of sleep optimization on glycemic&#xD;
      control in T1D. The purpose of this study is to determine the efficacy of a T1D-specific&#xD;
      sleep optimization intervention (Sleep-Opt) on the primary outcomes of sleep variability,&#xD;
      sleep duration and glycemic control (A1C); other glycemic parameters (glycemic variability,&#xD;
      time in range), diabetes distress, self-management behavior, QoL, and other patient reported&#xD;
      outcomes in working-age adults with T1D and habitual increased sleep variability or short&#xD;
      sleep duration. To achieve these aims, a randomized controlled trial is planned in 120&#xD;
      working age adults (18 to 65 years) with T1D. Participants will be screened for habitual&#xD;
      sleep variability (&gt; 1 hour/week) or insufficient sleep duration (&lt; 6.5 hours per night).&#xD;
      Eligible subjects will be randomized to the Sleep-Opt group or healthy living attention&#xD;
      control group for twelve weeks. A one-week run-in period is planned, with baseline measures&#xD;
      of sleep by actigraphy (sleep variability and duration), glycemia (A1C and related glycemic&#xD;
      measures: glycemic variability and time in range using continuous glucose monitoring), and&#xD;
      other secondary outcomes: diabetes distress, self-management behaviors, quality of life and&#xD;
      additional patient-reported outcomes. Sleep-Opt is a technology-assisted behavioral sleep&#xD;
      intervention that this study team developed that leverages the rapidly increasing public&#xD;
      interest in sleep tracking by consumers (+500% in 3 years). The behavioral intervention&#xD;
      employs four elements: a wearable sleep tracker, didactic content, an interactive smartphone&#xD;
      application, and brief telephone counseling. The attention control group will participate in&#xD;
      a healthy living information program. At midpoint (Week 6) completion (Week 12) and&#xD;
      post-program (Week 24), baseline measures will be repeated to determine differences between&#xD;
      the two groups and sustainability of the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Sleep optimization intervention will be compared to an attention control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep variability</measure>
    <time_frame>Change from week 0, 6, 12, 24</time_frame>
    <description>Standard deviation total sleep time for one week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep duration</measure>
    <time_frame>Change from weeks 0. 6, 12, 24</time_frame>
    <description>total sleep time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>Change from week 0. 6, 12, 24</time_frame>
    <description>HbA1c blood test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diabetes distress</measure>
    <time_frame>Change from week 0. 6, 12, 24</time_frame>
    <description>T1D Diabetes Distress Scale score- higher numbers indicate greater distress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-management behavior</measure>
    <time_frame>Change from week. 6, 12, 24</time_frame>
    <description>Self-Management Questionnaire score- higher numbers indicate better self-management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Change from week 0. 6, 12, 24</time_frame>
    <description>Patient Reported Outcomes Measure (PROMIS) fatigue scale score - higher numbers greater fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>Change from week 0. 6, 12, 24</time_frame>
    <description>Center for Epidemiological Studies - Depressed Mood score - Higher numbers more depressive mood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Sleep-Opt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12-week intervention that includes self-monitoring, goal setting, motivational enhancement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Living</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12-week intervention that includes weekly telephone contact, didactic content equal in time and attention to intervention group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sleep-Opt</intervention_name>
    <description>12-week behavioral intervention</description>
    <arm_group_label>Sleep-Opt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Healthy Living</intervention_name>
    <description>Healthy Living</description>
    <arm_group_label>Healthy Living</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults aged 18-65 years&#xD;
&#xD;
          -  clinical diagnosis of type 1 diabetes minimum of one year&#xD;
&#xD;
          -  reported habitual sleep variability (1 hour/week or more) or sleep duration less than&#xD;
             6.5 hrs/night during work- or weekdays (confirmed with actigraphy sleep watch)&#xD;
&#xD;
          -  a desire to improve sleep&#xD;
&#xD;
          -  own a smartphone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  insomnia symptoms&#xD;
&#xD;
          -  at high risk for obstructive sleep apnea&#xD;
&#xD;
          -  severe hypoglycemia episode in the past 6 months (e.g. loss of consciousness)&#xD;
&#xD;
          -  A1C greater than 10%&#xD;
&#xD;
          -  rotating shift or night shift work&#xD;
&#xD;
          -  use of sleep medications/aids&#xD;
&#xD;
          -  renal impairment (estimated glomerular filtration rate &lt; 45 ml/min)&#xD;
&#xD;
          -  significant current medical morbidities (such as heart failure, cirrhosis, chronic&#xD;
             obstructive pulmonary disease requiring oxygen, active treatment for cancer,&#xD;
             depression, history of stroke with neurological deficits&#xD;
&#xD;
          -  breast feeding, pregnant, or planning pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Martyn-Nemeth, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamela Martyn-Nemeth, PhD</last_name>
    <phone>312-996-7903</phone>
    <email>pmartyn@uic.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sirimon Reutrakul, MD</last_name>
    <email>sreutrak@uic.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Illinois Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Martyn-Nemeth, PhD</last_name>
      <phone>312-996-7903</phone>
      <email>pmartyn@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sirimon Reutrakul, MD</last_name>
      <phone>3129966060</phone>
      <email>sreutrak@uic.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Pamela Martyn-Nemeth</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

